ScholarLens Back to search
2010•Journal watchRequires access

Tenofovir/FTC vs. Abacavir/3TC: Results from the ASSERT Study

Keith Henry

Open publisher page 0 citations

Abstract

Comparisons of abacavir and tenofovir continue to be of great interest. In the open-label ASSERT study (sponsored by the manufacturer of abacavir), 392

About this research paper

What this paper is about

Comparisons of abacavir and tenofovir continue to be of great interest. In the open-label ASSERT study (sponsored by the manufacturer of abacavir), 392

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Comparisons of abacavir and tenofovir continue to be of great interest. In the open-label ASSERT study (sponsored by the manufacturer of abacavir), 392

Key concepts: Abacavir, Tenofovir, Medicine, Human immunodeficiency virus (HIV), Virology, Antiretroviral therapy, Viral load

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Tenofovir/FTC vs. Abacavir/3TC: Results from the ASSERT Study — Research Paper | ScholarLens